New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
06:12 EDTAAPL, THLD, TM, INTC, AMGN, NSANY, MSFT, GSK, HMC, VLKAY, GM, FIATY, FOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: As U.S. companies hold near record amounts of cash, many are surprisingly cash poor at home. That means there could be unseen limits on their ability to pay dividends and buy back shares, the Wall Street Journal reports...In November, U.S. sales of cars and light trucks were the strongest in over four years, jumping 15% to 1.14M compared with a year ago. The seasonally adjusted annualized sales rate was 15.5M, the highest since January 2008, according to Autodata, the Wall Street Journal reports...REUTERS: Fed bankers appear satisfied with their latest monetary stimulus, but there's some disagreement over how strongly to continue purchasing bonds. Boston Fed President Rosengren said there was a "strong case" for the Fed to stay the course, while St. Louis Fed President Bullard said they shouldn’t replace its expiring 'Operation Twist' program on a dollar-for-dollar basis, Reuters reports...U.S. rail and trucking companies are making big investments on both sides of the border with Mexico to capitalize on booming trade between the two countries, Reuters reports...BLOOMBERG: Four experimental cancer treatments that may one day help gravely ill children are facing review by U.S. pediatric advisers. The medicines from GlaxoSmithKline (GSK), Amgen (AMGN) Threshold (THLD) and Boehringer Ingelheim have the potential to treat children with a variety of tumors and fast-spreading leukemia, Bloomberg reports...The move by Microsoft (MSFT) and Intel (INTC) to combat Apple’s (AAPL) iPad in the $63.2B tablet market is getting off to a slow start, Bloomberg reports.
News For GM;F;FIATY;VLKAY;HMC;NSANY;TM;GSK;AMGN;THLD;MSFT;INTC;AAPL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 >>
January 25, 2016
17:23 EDTAMGNAmgen announces FDA acceptance of BLA for ABP 501
Subscribe for More Information
17:21 EDTNSANYNissan CEO says considering expanded collaboration with Renault, Nikkei says
Subscribe for More Information
16:00 EDTMSFT, AAPLOptions Update; January 25, 2016
Subscribe for More Information
14:18 EDTAAPLApple volatility increases into Q1 and outlook
Subscribe for More Information
14:17 EDTAAPLVIX methodology for Apple VXAPL +3% to 39.17 into Q1 & outlook
Subscribe for More Information
14:06 EDTAAPLApple technical comments ahead of earnings, potential bearish pattern
There is a potential bearish head and shoulders top, which is most easily seen on a 3-year chart. The neckline for the pattern is at the $100 area on a closing basis, and in recent sessions the pattern has been both active and inactive as price crossed that line. If the news is bearish, a breakdown below $100 would see the pattern become active. Downside potential for the pattern would be to the $70 to $66 area. If the news is a bullish surprise, and sentiment has turned negative on the name which could add to short-cover demand, the counter-reaction up may be as large as pattern suggests is possible on the downside. It could mean in time a retaking of the $130 area or higher. The life high for the shares is at $134.54.
12:59 EDTAAPLApple executives unsatisfied with progress of 'Project Titan,' AppleInsider says
Subscribe for More Information
11:05 EDTGSKOncoMed price target lowered to $29 from $43 at Piper Jaffray
Subscribe for More Information
10:55 EDTAMGNRegeneron slips after analyst says sell to avoid risk from Amgen patent suit
Shares of Regeneron Pharmaceuticals (REGN) fell in morning trading after an analyst at Chardan downgraded the stock to Sell, citing risk from a patent lawsuit in which the biopharmaceutical company is involved. CHARDAN SAYS SELL: Chardan Capital Markets analyst Gbola Amusa downgraded Regeneron to Sell from Neutral this morning, while reducing his price target on shares to $400 from $525. In a note to clients, Amusa said he believes that Regeneron is likely to face significant risks from the upcoming patent infringement case for Praluent. The suit could be a key driver of the company's share price performance in the near future, the analyst said. Regeneron, along with its partner Sanofi (SNY), launched Praluent in the U.S. last year, after the October 2014 filing of a patent infringement suit by Amgen (AMGN) relating to patents for "monoclonal antibodies that bind PCSK9," Amusa noted. The analyst believes that since Regeneron and Sanofi "likely" infringe Amgen's patents for Repatha, the Regeneron-Sanofi partnership could seek to settle the ahead of the trial by agreeing to pay 10%-20% or more of royalties to Amgen for U.S. Praluent sales. Amusa said that "such an outcome we estimate could transfer roughly $750M of operating income per year to Amgen." Further, Amusa said that catalysts surrounding the patent infringement trial are "likely to play out from late February to late March," and concedes that "both sides have good reasons to settle this case for a reasonable royalty." INCREASING COMPETITION: Amusa also noted that he sees increasing competitive risks in 2016 to Regeneron's Eylea from Novartis (NVS) and its partner Ophthotech (OPHT), which continue to progress Fovista into Phase III trials in wet AMD. WHAT'S NOTABLE: Roth Capital upgraded Regeneron to Buy from Neutral on January 19, based on valuation, as the firm said shares do not reflect the value of the company's upcoming catalysts. The firm also raised its price target to $555 from $543. The same day, Credit Suisse initiated Regeneron with a Neutral rating and $552 target. PRICE TARGET: Regeneron slipped 1.4% to $476.02 in morning trading.
10:22 EDTVLKAYVW workers reject 'unrealistic' productivity goal, Bloomberg says
Subscribe for More Information
10:03 EDTAAPLApple's iPhone 5se to likely come with faster A9/M9 chips, 9to5Mac reports
Subscribe for More Information
09:32 EDTAAPL, MSFT, INTCApple Active equity options trading on open
Subscribe for More Information
08:22 EDTMSFTMajesco and Microsoft announce favorable court judgment
Subscribe for More Information
07:16 EDTINTCIntel upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Deepon Nag upgraded Intel to Oupterform and raised his price target to $35 from $34 on shares. The analyst believes the combination of easier comps and moderating competition in tablets and smartphones should result in a PC shipment growth acceleration into CY16. Additionally, Nag said Intel has been undershipping end-demand for all of 2015, which adds to estimates and potential upside as the PC supply chain replenishes inventories.
07:06 EDTAAPLApple volatility elevated into Q1 and outlook
Apple 1/29/16 call option implied volatility is at 57, February is at 38; compared to its 52-week range of 18 to 55, suggesting large near term price movement into the expected release of Q1 results on January 26.
06:53 EDTGSKGlaxo, Astra, J&J partner with universities in drug research fund, Reuters says
Subscribe for More Information
06:44 EDTAAPLApple to release new iPhone, iPad Air 3 in 1H16, AppleInsider says
Apple is planning to launch a 4-inch iPhone as well as the iPad Air 3 in the first half of the year, AppleInsider reports, citing KGI analyst Ming-Chi Kuo. Reference Link
06:30 EDTFFord to shutter operations in Japan, Indonesia, Reuters reports
Ford will shutter operations in Japan and Indonesia this year since it sees "no reasonable path to profitability" in the two nations, Reuters reports. The car maker will exit all areas of its business, including dealerships and imports of Ford and Lincoln vehicles, in the two countries, the report says, citing an email from Asia Pacific President Dave Schoch to all employees in the region. Reference Link
05:51 EDTAAPLOptions expected to be active: TYC JCI TWTR SUNE AAPL PG HAL AMZN FB
Subscribe for More Information
05:36 EDTINTCStocks with implied volatility below IV index mean; CELG INTC
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use